CA2275379C - Use of pramipexole in the treatment of restless legs syndrome - Google Patents
Use of pramipexole in the treatment of restless legs syndrome Download PDFInfo
- Publication number
- CA2275379C CA2275379C CA002275379A CA2275379A CA2275379C CA 2275379 C CA2275379 C CA 2275379C CA 002275379 A CA002275379 A CA 002275379A CA 2275379 A CA2275379 A CA 2275379A CA 2275379 C CA2275379 C CA 2275379C
- Authority
- CA
- Canada
- Prior art keywords
- pramipexole
- restless legs
- legs syndrome
- dihydrochloride
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 title claims abstract description 25
- 229960003089 pramipexole Drugs 0.000 title claims abstract description 25
- 208000005793 Restless legs syndrome Diseases 0.000 title claims abstract description 22
- 150000003839 salts Chemical class 0.000 claims description 8
- FASDKYOPVNHBLU-UHFFFAOYSA-N N6-Propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine Chemical compound C1C(NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-UHFFFAOYSA-N 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 4
- 102000011923 Thyrotropin Human genes 0.000 description 2
- 108010061174 Thyrotropin Proteins 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 1
- KWFASKPXXSVNIQ-UHFFFAOYSA-N 6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,4-diamine Chemical compound C1C(CCC)CC(N)C2=C1SC(N)=N2 KWFASKPXXSVNIQ-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- QMNWXHSYPXQFSK-UHFFFAOYSA-N hydron;6-n-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine;dichloride Chemical compound Cl.Cl.C1C(NCCC)CCC2=C1SC(N)=N2 QMNWXHSYPXQFSK-UHFFFAOYSA-N 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Medicinal Preparation (AREA)
- Liquid Crystal Substances (AREA)
- Semiconductor Memories (AREA)
Abstract
The present invention provides the use of pramipexole in the treatment of restless legs syndrome.
Description
UlJU,r ~,r USE OF PRAMIPEXOLE IN THE TREATMENT OF RESTLESS LEGS
SYNDROME
FIELD OF THE INVENTION
The present invention relates to the use of pramipexole or 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzo-thiazole or the (-)-enantiomers thereof, and the pharmacologically acceptable salts thereof, in the treatment of restless leg syndrome.
BACKGROUND OF THE INVENTION
Restless leg syndrome (RLS) is a neurosensorimotor disorder with parestethesias, steep disturbances and, in most cases, periodic limb movements of sleep (PLMS).
Pramipexole is a dopamine-D3/DZ agonist the synthesis of which is described in European Patent 186 087 and its counterpart, U.S. Patent 4,886,812. It is known primarily for the treatment of schizophrenia and Parkinson's disease. It is known from German patent application DE 38 43 227 that pramipexole lowers the plasma level of prolactin. Also, this European patent application discloses the use of pramipexole in the treatment of drug dependency. Further, it is known from German patent application DE 39 33 738 that pramipexole can be used to decrease abnormal high levels of thyroid stimulating hormone (TSH). U.S, patent 5,112,842 discloses the transdermal administration of the compounds and transdermal systems containing these active compounds. U.S. Patent No. 6,191,153 describes pramipexole as an antidepressant agent, while European Patent No. EP 797,439 B l discloses the neuroprotective effects of pramipexole.
Surprisingly and unexpectedly, it has been found that pramipexole and the pharmacologically acceptable salts thereof can be used in the treatment of restless leg syndrome.
SUMMARY OF THE INVENTION
The present invention particularly provides a method for treatment of restless Legs syndrome in a patient suffering from or susceptible to such condition comprising the administration of an effective amount of pramipexole. By pramipexole is meant 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazole, its (-)-enantiomer thereof, and pharmacologically acceptable salts thereof especially (-)-2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazole dihydrochloride (H20).
SYNDROME
FIELD OF THE INVENTION
The present invention relates to the use of pramipexole or 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzo-thiazole or the (-)-enantiomers thereof, and the pharmacologically acceptable salts thereof, in the treatment of restless leg syndrome.
BACKGROUND OF THE INVENTION
Restless leg syndrome (RLS) is a neurosensorimotor disorder with parestethesias, steep disturbances and, in most cases, periodic limb movements of sleep (PLMS).
Pramipexole is a dopamine-D3/DZ agonist the synthesis of which is described in European Patent 186 087 and its counterpart, U.S. Patent 4,886,812. It is known primarily for the treatment of schizophrenia and Parkinson's disease. It is known from German patent application DE 38 43 227 that pramipexole lowers the plasma level of prolactin. Also, this European patent application discloses the use of pramipexole in the treatment of drug dependency. Further, it is known from German patent application DE 39 33 738 that pramipexole can be used to decrease abnormal high levels of thyroid stimulating hormone (TSH). U.S, patent 5,112,842 discloses the transdermal administration of the compounds and transdermal systems containing these active compounds. U.S. Patent No. 6,191,153 describes pramipexole as an antidepressant agent, while European Patent No. EP 797,439 B l discloses the neuroprotective effects of pramipexole.
Surprisingly and unexpectedly, it has been found that pramipexole and the pharmacologically acceptable salts thereof can be used in the treatment of restless leg syndrome.
SUMMARY OF THE INVENTION
The present invention particularly provides a method for treatment of restless Legs syndrome in a patient suffering from or susceptible to such condition comprising the administration of an effective amount of pramipexole. By pramipexole is meant 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazole, its (-)-enantiomer thereof, and pharmacologically acceptable salts thereof especially (-)-2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazole dihydrochloride (H20).
2-Amino-6-n-propyl-amino-4,5,6,7-tetrahydrobenzothiazole, particularly the (-)-enantiomer thereof, and the pharmacologically acceptable acid addition salts thereof can be given for treating RSL. The form of conventional galenic 6156.P CP
preparations consist essentially of an inert pharmaceutical carrier and an effective dose of the active substance; e.g., plain or coated tablets, capsules, lozenges, powders, solutions, suspensions, emulsions, syrups, suppositories, etc.
Preferred are tablets comprising 0.88 (0.125), 0.18 (0.25), 0.? (1.0), 088 (1.25) and 1.1 (1.5) mg of Pramipexole base (mg Pramipexole 2HC1), respectively, and further comprising mannitol, maize starch, colloidal silica, polividone and magnesium stearate as excipients.
The effective dose range is 0.001 to 10.0 mg/day and patient, preferred between 0.001 and 6, more preferred between 0.01 to 6 and especially preferred .
between 0.75 and 4.5 mg/day and patient p.o. In addition to being administered by oral or intravenous route pramipexole may also be administered transdermally or by inhalation.
Dosages should be increased gradually from a starting dose of about 0.264 mg of base per day and then increased every 5-7 days. Providing patients do not experience intolerable side effects, the dosage should be titrated to achieve a maximal therapeutic effect.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
The present invention is seen more fully by the examples given below:
In a pilot study on Restless Leg Syndrome, 10 patients have been treated with pramipexole in a crossover design. The patients received up to 1.5 mg a day of pramipexole over 4 weeks. After the first treatment period there is a two week wash-out period and an additional 4-week treatment period.
Since the symptoms of RLS are quite obvious, their improvement from treatment was obvious to the investigator.
In a preferred embodiment, the invention comprises a commercial package comprising a container containing therein 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazole, its (-)-enantioiner or a pharmaceutically acceptable salt thereof and written matter which states that the contents of the container are for use in treating restless legs syndrome. In another preferred embodiment, the invention comprises a commercial package comprising a container containing therein pramipexole, its dihydrochloride or its dihydrochloride-(HZO) and written matter which states that the contents of the container are for use in treating restless legs syndrome.
preparations consist essentially of an inert pharmaceutical carrier and an effective dose of the active substance; e.g., plain or coated tablets, capsules, lozenges, powders, solutions, suspensions, emulsions, syrups, suppositories, etc.
Preferred are tablets comprising 0.88 (0.125), 0.18 (0.25), 0.? (1.0), 088 (1.25) and 1.1 (1.5) mg of Pramipexole base (mg Pramipexole 2HC1), respectively, and further comprising mannitol, maize starch, colloidal silica, polividone and magnesium stearate as excipients.
The effective dose range is 0.001 to 10.0 mg/day and patient, preferred between 0.001 and 6, more preferred between 0.01 to 6 and especially preferred .
between 0.75 and 4.5 mg/day and patient p.o. In addition to being administered by oral or intravenous route pramipexole may also be administered transdermally or by inhalation.
Dosages should be increased gradually from a starting dose of about 0.264 mg of base per day and then increased every 5-7 days. Providing patients do not experience intolerable side effects, the dosage should be titrated to achieve a maximal therapeutic effect.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
The present invention is seen more fully by the examples given below:
In a pilot study on Restless Leg Syndrome, 10 patients have been treated with pramipexole in a crossover design. The patients received up to 1.5 mg a day of pramipexole over 4 weeks. After the first treatment period there is a two week wash-out period and an additional 4-week treatment period.
Since the symptoms of RLS are quite obvious, their improvement from treatment was obvious to the investigator.
In a preferred embodiment, the invention comprises a commercial package comprising a container containing therein 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazole, its (-)-enantioiner or a pharmaceutically acceptable salt thereof and written matter which states that the contents of the container are for use in treating restless legs syndrome. In another preferred embodiment, the invention comprises a commercial package comprising a container containing therein pramipexole, its dihydrochloride or its dihydrochloride-(HZO) and written matter which states that the contents of the container are for use in treating restless legs syndrome.
Claims (10)
1. ~Use of the compound 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazole, its (-)-enantiomer or a pharmaceutically acceptable salt thereof to treat restless legs syndrome.
2. ~Use of pramipexole, its dihydrochloride or its dihydrochloride-(H2O) to treat restless legs syndrome.
3. ~Use of about 0.01-10.0 mg/day of pramipexole to treat restless legs syndrome.
4. ~Use of about 0.01-10.0 mg/day of pramipexole, its dihydrochloride or its dihydrochloride-(H2O) to treat restless legs syndrome.
5. ~Use of the compound 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazole, its (-)-enantiomer or a pharmaceutically acceptable salt thereof to prepare a medicament to treat restless legs syndrome.
6. ~Use of pramipexole, its dihydrochloride or its dihydrochloride-(H2O) to prepare a medicament to treat restless legs syndrome.
7. ~Use of pramipexole, its dihydrochloride or its dihydrochloride-(H2O) to prepare a medicament containing about 0.01-10.0 mg thereof to treat restless legs syndrome.
8. ~Use of pramipexole to prepare a medicament containing about 0.01-10.0 mg thereof to treat restless legs syndrome.
9. ~A commercial package comprising a container containing therein 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazole, its (-)-enantiomer or a pharmaceutically acceptable salt thereof and written matter which states that the contents of the container are for use in treating restless legs syndrome.
10. ~A commercial package comprising a container containing therein pramipexole, its dihydrochloride or its dihydrochloride-(H2O) and written matter which states that the contents of the container are for use in treating restless legs syndrome.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19701619.7 | 1997-01-17 | ||
| DE19701619A DE19701619B4 (en) | 1997-01-17 | 1997-01-17 | Use of pramipexole for the treatment of restless legs syndrome |
| PCT/US1998/000216 WO1998031362A1 (en) | 1997-01-17 | 1998-01-16 | Use of pramipexole in the treatment of restless legs syndrome |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2275379A1 CA2275379A1 (en) | 1998-07-23 |
| CA2275379C true CA2275379C (en) | 2006-11-28 |
Family
ID=7817708
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002275379A Expired - Lifetime CA2275379C (en) | 1997-01-17 | 1998-01-16 | Use of pramipexole in the treatment of restless legs syndrome |
Country Status (23)
| Country | Link |
|---|---|
| EP (1) | EP0989850B1 (en) |
| JP (2) | JP4406685B2 (en) |
| KR (2) | KR20000070234A (en) |
| CN (1) | CN1117564C (en) |
| AT (1) | ATE281165T1 (en) |
| AU (1) | AU723119B2 (en) |
| BG (1) | BG64614B1 (en) |
| CA (1) | CA2275379C (en) |
| CZ (1) | CZ289863B6 (en) |
| DE (2) | DE19701619B4 (en) |
| ES (1) | ES2231959T3 (en) |
| FI (1) | FI120135B (en) |
| HU (1) | HU226564B1 (en) |
| NO (1) | NO321151B1 (en) |
| NZ (2) | NZ336804A (en) |
| PL (1) | PL190898B1 (en) |
| PT (1) | PT989850E (en) |
| RO (1) | RO120757B1 (en) |
| RU (1) | RU2192252C2 (en) |
| SI (1) | SI20060A (en) |
| SK (1) | SK284264B6 (en) |
| WO (1) | WO1998031362A1 (en) |
| ZA (1) | ZA98420B (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6001861A (en) * | 1998-01-16 | 1999-12-14 | Pharmacia & Upjohn Company | Use of pramipexole in the treatment of restless legs syndrome |
| DE19701619B4 (en) * | 1997-01-17 | 2007-10-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of pramipexole for the treatment of restless legs syndrome |
| SE9803760D0 (en) * | 1998-11-04 | 1998-11-04 | Jan Hedner | Methods to treat and diagnose the restless legs syndrome and the corresponding agents |
| DE19938825A1 (en) * | 1999-08-19 | 2001-04-26 | Boehringer Ingelheim Pharma | Active ingredient combination with clonidine |
| DE10220230A1 (en) * | 2002-05-06 | 2003-11-27 | Sanol Arznei Schwarz Gmbh | Use of Rotigotine to treat restless leg syndrome |
| EP1588704A1 (en) * | 2004-04-22 | 2005-10-26 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders |
| EP1940398A1 (en) * | 2005-10-18 | 2008-07-09 | Boehringer Ingelheim International GmbH | Use of pramipexol for treating moderate to severe restless legs syndrome (rls) |
| JP5769923B2 (en) * | 2006-04-03 | 2015-08-26 | テバ ファーマシューティカル インダストリーズ リミティド | Use of rasagiline for the treatment of restless legs syndrome |
| TR200906997A1 (en) | 2009-09-11 | 2011-03-21 | Sanovel �La� San. Ve T�C. A. �. | Pramipexole pharmaceutical compositions. |
| TR200907554A1 (en) | 2009-10-06 | 2011-04-21 | Sanovel İlaç San.Ve Ti̇c.A.Ş. | Orally dispersible pramipexole compositions. |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE45735T1 (en) * | 1984-12-22 | 1989-09-15 | Thomae Gmbh Dr K | TETRAHYDRO-BENZTHIAZOLE, THEIR PRODUCTION AND USE AS INTERMEDIATE OR MEDICINAL PRODUCTS. |
| DE3843227A1 (en) * | 1988-12-22 | 1990-07-05 | Boehringer Ingelheim Kg | NEW USE OF 2-AMINO-6-N-PROPYLAMINO-4,5,6,7-TETRAHYDROBENZTHIAZOLE |
| DE3933738A1 (en) * | 1989-10-10 | 1991-04-11 | Boehringer Ingelheim Kg | NEW USE OF 2-AMINOTHIAZOL DERIVATIVES (TSH) |
| DE3937271A1 (en) * | 1989-11-09 | 1991-05-16 | Boehringer Ingelheim Kg | TRANSDERMAL APPLICATION OF 2-AMINO-6-N-PROPYLAMINO-4,5,6,7-TETRAHYDROBENZOTHIAZOLE |
| DE4125446A1 (en) * | 1991-08-01 | 1993-02-04 | Uwe Dipl Ing Behmann | METHOD AND DEVICE FOR ELECTRICAL SHORT-CIRCUIT CHECKING AND LOCATION FOR CABLES, ESPECIALLY FOR CABLES, ELECTRICAL RAILWAYS |
| US5598352A (en) * | 1994-09-30 | 1997-01-28 | Cirrus Logic, Inc. | Method and apparatus for audio and video synchronizing in MPEG playback systems |
| US5650420A (en) * | 1994-12-15 | 1997-07-22 | Pharmacia & Upjohn Company | Pramipexole as a neuroprotective agent |
| DE19701619B4 (en) * | 1997-01-17 | 2007-10-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of pramipexole for the treatment of restless legs syndrome |
-
1997
- 1997-01-17 DE DE19701619A patent/DE19701619B4/en not_active Expired - Lifetime
-
1998
- 1998-01-16 RU RU99118211/14A patent/RU2192252C2/en active
- 1998-01-16 NZ NZ336804A patent/NZ336804A/en not_active IP Right Cessation
- 1998-01-16 JP JP53336998A patent/JP4406685B2/en not_active Expired - Lifetime
- 1998-01-16 CZ CZ19992478A patent/CZ289863B6/en not_active IP Right Cessation
- 1998-01-16 WO PCT/US1998/000216 patent/WO1998031362A1/en not_active Ceased
- 1998-01-16 EP EP98903378A patent/EP0989850B1/en not_active Expired - Lifetime
- 1998-01-16 KR KR1019997006461A patent/KR20000070234A/en not_active Ceased
- 1998-01-16 SI SI9820013A patent/SI20060A/en active Search and Examination
- 1998-01-16 PT PT98903378T patent/PT989850E/en unknown
- 1998-01-16 KR KR1020057012562A patent/KR100761774B1/en not_active Expired - Lifetime
- 1998-01-16 AU AU60168/98A patent/AU723119B2/en not_active Expired
- 1998-01-16 RO RO99-00818A patent/RO120757B1/en unknown
- 1998-01-16 AT AT98903378T patent/ATE281165T1/en active
- 1998-01-16 PL PL334498A patent/PL190898B1/en unknown
- 1998-01-16 ES ES98903378T patent/ES2231959T3/en not_active Expired - Lifetime
- 1998-01-16 NZ NZ510007A patent/NZ510007A/en not_active IP Right Cessation
- 1998-01-16 CA CA002275379A patent/CA2275379C/en not_active Expired - Lifetime
- 1998-01-16 CN CN98801721A patent/CN1117564C/en not_active Expired - Lifetime
- 1998-01-16 SK SK920-99A patent/SK284264B6/en not_active IP Right Cessation
- 1998-01-16 DE DE69827387T patent/DE69827387T2/en not_active Expired - Lifetime
- 1998-01-16 HU HU0001913A patent/HU226564B1/en unknown
- 1998-01-19 ZA ZA9800420A patent/ZA98420B/en unknown
-
1999
- 1999-07-01 BG BG103543A patent/BG64614B1/en unknown
- 1999-07-07 NO NO19993360A patent/NO321151B1/en not_active IP Right Cessation
- 1999-07-16 FI FI991616A patent/FI120135B/en not_active IP Right Cessation
-
2008
- 2008-10-22 JP JP2008272286A patent/JP2009062388A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6001861A (en) | Use of pramipexole in the treatment of restless legs syndrome | |
| EP1257271B1 (en) | Use of pramipexole for the treament of tobacco/nicotine addiction | |
| JP2009062388A (en) | Use of pramipexole in the treatment of restless leg syndrome | |
| JP2007217432A (en) | Use of pramipexole as a neuroprotective agent | |
| PL195043B1 (en) | Agents with an antidepressive effect | |
| HK1024408B (en) | Use of pramipexole in the treatment of restless legs syndrome | |
| WO2007007133A2 (en) | Composition for treatment of psychosis | |
| WO2004037238A1 (en) | New uses of deramciclane |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20180116 |